Vascular dementia

U.S. Pharmacist

Volumn 35, Issue 1, 2010, Pages 46-48

  Robishaw, Cristina ^b   Beadle, Marie ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; BLOOD PRESSURE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOLOGY; PHARMACIST; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; TREATMENT DURATION; UNITED STATES; WHITE MATTER;

EID: 76149109443     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (24)

1. Wright CB. Etiology, clinical manifestations, and diagnosis of vascular dementia. Waltham, MA: UpToDate Inc; June 2009. http://uptodateonline.com/ online/content/topic.do?topicKey=nuroegen/7230&view=print. Accessed October 8, 2009.
2. Rojas-Fernandez CH, Moorhouse P. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann Pharmacother. 2009;43:1310-1323.
3. Knopman DS. Dementia and cerebrovascular disease. Mayo Clin Proc. 2006;81:223-230.
4. Chapman DP, Williams SM, Strine TW, et al. Dementia and its implications for public health. Prev Chronic Dis. 2006;3:A34.
5. Pinkston JB, Alekseeva N, Gonzàlez-Toledo E. Stroke and dementia. Neurol Res. 2009;31:824-831.
6. Fratiglioni L, Rocca WA. Epidemiology of dementia. In: Boller F, Cappa S, eds. Handbook of Neuropsychology: Vol. 6: Aging and Dementia. 2nd ed. Amsterdam, Netherlands: Elsevier Science; 2001.
7. Centers for Disease Control and Prevention. Stroke facts and statistics. www.cdc.gov/Stroke/stroke-facts.htm. Accessed October 12, 2009.
8. Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc. 2006;81:1350-1358.
9. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebocontrolled study. Neurology. 2003;61:497-486.
10. Black S, Román GC, Gelmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323-2330.
11. Wilkinson D, Róman G, Salloway S, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry. July 21, 2009:Epub.
12. Alzheimer's Association. Vascular dementia. www.alz.org/alzheimers- disease-vascular-dementia.asp. Accessed October 9, 2009.
13. Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69:448-458.
14. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2006;(1):CD004746.
15. Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008;24:2561-2574.
16. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia; a randomized, placebo-controlled trial (MMM300). Stroke. 2002;33:1834-1839.
17. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-305.
18. Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009;57:536-546.
19. Clinical Trials.gov. List results: vascular dementia. www.clinicaltrials.gov/ct2/results?term=vascular+dementia . Accessed October 7, 2009.
20. Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc.1989;37:549-555.
21. European pentoxifylline multi-infarct dementia study. Eur Neurol. 1996;36:315-321.
22. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39:1647-1652.
23. Albers GW, Amarenco P, Easton D, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(suppl 6):630S-669S.
24. Micromedex Healthcare Series [by subscription]. www.thomsonhc.com. ezproxy.samford.edu/home/dispatch. Accessed October 12, 2009.